Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02804750 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate CORT125134 in Participants With Cushing's Syndrome
A Phase 2 study of Cushing's Syndrome, sponsored by Corcept Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 20
- Study locations
NCT02804750: Completed Phase 2 study of Cushing's Syndrome, sponsored by Corcept Therapeutics.
NCT02804750 is a Phase 2 study of Cushing's Syndrome that has completed, run by Corcept Therapeutics. The registered enrollment target is 35 participants, below the 761-participant average among 5 other Cushing's Syndrome trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02804750, a Phase 2 study of Cushing's Syndrome, has completed, sponsored by Corcept Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 20
- Study locations
Study Summary
Cushing's syndrome is a relatively rare disorder caused by prolonged exposure to high levels of the glucocorticoid hormone cortisol. Cushing's syndrome may result from elevated endogenous or exogenous sources of cortisol. Endogenous Cushing's syndrome resulting from cortisol overproduction by the adrenal glands is the subject of this protocol. Patients with exogenous Cushing's syndrome, which develops as a side effect of chronic administration of high doses of glucocorticoids, were not eligible for enrollment in this study. The purpose of this study was to evaluate the safety and efficacy of CORT125134 for treatment of endogenous Cushing's syndrome. The multicenter study was conducted in the United States and in Europe.
Primary Outcome
All treatment-emergent adverse events were recorded and summarized.
Conditions Studied
Interventions
- DRUG CORT125134
Study Locations (20)
Other
- - Budapest
- - Pécs
- - Cuneo
- - Messina
- - Milan
- - Naples
- - Orbassano
- - Roma
Florida
- - Fort Lauderdale
- - Miami
California
- - Laguna Hills
Colorado
- - Aurora
Indiana
- - Indianapolis
Kentucky
- - Covington
Minnesota
- - Rochester
Missouri
- - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2016-06 |
| Est. Completion | 2018-09 |
| Phase | Phase 2 |
What the finished NCT02804750 record still lists
NCT02804750 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 761-participant average among 5 other Cushing's Syndrome trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Cushing's Syndrome appearing as the primary indexed condition, and to 1 intervention - of which CORT125134 is the first listed.
NCT02804750 names 20 study sites across 12 states, led by Other, Florida, California.
Frequently Asked Questions
What is clinical trial NCT02804750 about?
NCT02804750 is a clinical study titled "Study to Evaluate CORT125134 in Participants With Cushing's Syndrome". Cushing's syndrome is a relatively rare disorder caused by prolonged exposure to high levels of the glucocorticoid hormone cortisol. Cushing's syndrome may result from elevated endogenous or exogenous sources of cortisol. Endogenous Cushing's syndrome resulting from cortisol overproduction by the ad...
What is the current status of trial NCT02804750?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2016-06. Estimated completion is 2018-09.
What conditions does trial NCT02804750 study?
This clinical trial studies the following conditions: Cushing's Syndrome.
What interventions are being tested in trial NCT02804750?
The interventions under investigation include: CORT125134 (DRUG).
Who is sponsoring clinical trial NCT02804750?
This trial is sponsored by Corcept Therapeutics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02804750 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Indiana, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cushing's Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Prospective Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Ectopic Cushing Syndrome
RECRUITING · Phase 2
-
Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism
RECRUITING · Phase 2
-
Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex
COMPLETED
-
Novel Mediators of the Lipodystrophy and Metabolic Consequences of Cushing's Disease
COMPLETED
-
Dose Response Relationship for Single Doses of Corticotropin Releasing Hormone (CRH) in Normal Volunteers and in Patients With Adrenal Insufficiency
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia